BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Часто задаваемые вопросы
В каком секторе работает BioNxt Solutions Inc. (BNXTF)?
BioNxt Solutions Inc. относится к сектору Здравоохранение.
Какова текущая цена акций BioNxt Solutions Inc. (BNXTF)?
По последним данным, цена акций BioNxt Solutions Inc. составляет 0,26 $, предыдущее закрытие — 0,26 $.
Выплачивает ли BioNxt Solutions Inc. (BNXTF) дивиденды?
Нет, BioNxt Solutions Inc. не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у BioNxt Solutions Inc. (BNXTF)?
У компании BioNxt Solutions Inc. бета 1.501, что указывает на повышенную волатильность по сравнению с рынком.
